Drug development collaboration for Dr Reddy's and 7TM Pharma

Indian biotech company Dr Reddy's Laboratories is to collaborate with Danish firm 7TM Pharma on selected drug targets in the area of metabolic disorders.

Under the terms of the agreement, the two companies Pharma will identify clinical candidates for pre-selected targets and jointly develop these candidates from the pre-clinical stage up to Phase IIa (proof-of-concept). On successful completion of a Phase IIa study, the companies may either license-out the candidate for further development and commercialisation to a larger pharmaceutical company or continue the further co-development and commercialisation jointly.

Mette Kirstine Agger, 7TM Pharma's ceo, said: "It is exciting to be working with Dr Reddy's, as they have developed strong R&D capabilities and combining this with 7TMs expertise in the GPCR area and SD3 (7TM's technology platform) we are looking forward to a fruitful collaboration."

Dr Rajinder Kumar, president of research, development and commercialisation at Dr Reddy's, said: "7TM has established a track record as one of the leading drug discovery companies focusing on GPCRs, and we are excited at the prospects of combining 7TM's capabilities with Dr. Reddy's to discover and develop innovative products."

The financial terms of the agreement have not been disclosed.